Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study. (September 2016)

• Record Type: Journal Article
• Authors: Wu, Ai-Wen; Yuan, Peng; Li, Zi-Yu; Tang, Lei; Bu, Zhao-De; Ren, Hui; Ji, Jia-Fu
• Is Part Of: Future oncology. Volume 12:Number 18(2016)
• Page Start: 2107
• Page End: 2116
• Publication Date: 2016-09
• Subjects: capecitabine -- gastric cancer -- induction chemotherapy -- liver metastasis -- paclitaxel; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0145
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To determine the overall survival rate, radical resection rate, objective response rate and safety of capecitabine plus paclitaxel induction chemotherapy in gastric cancer patients with liver metastases.Patients & methods: A total of 30 patients (median age: 59.5 years) diagnosed as gastric adenocarcinoma with liver metastasis received ≥3 cycles of capecitabine and paclitaxel therapy followed by radical resection 4–6 weeks after termination of chemotherapy.Results: The median survival time was 11.4 months, and the objective response rate was 53.3%. The radical resection rate was 23.3% (95% CI: 9.9–42.3). Major toxicities included grade 3 neutropenia (10.0%) and grade 3 diarrhea (3.3%).Conclusion: Capecitabine plus paclitaxel chemotherapy may be effective and safe to improve overall survival and the resection rate of gastric cancer patients with liver metastases.ClinicalTrials.gov identifier: NCT0116704.